FDA Approves Inavolisib Combo in PIK3CA+ Advanced Breast Cancer

News
Article

Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.

Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.

Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.

The FDA has approved inavolisib (Itovebi) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) for those with endocrine-resistant, hormone receptor–positive, HER2-negative, locally advanced or metastatic breast cancer harboring PIK3CA mutations, according to a news release from the agency.1

The FoundationOne Liquid CDx assay also received approval as a companion diagnostic for use in identifying those who may be eligible to receive treatment with this regimen.

Supporting data for the approval came from the phase 3 INAVO120 trial (NCT04191499), in which investigators assessed treatment among 325 patients with disease progression on prior adjuvant endocrine therapy.

Data showed a median progression-free survival of 15.0 months (95% CI, 11.3-20.5) with the inavolisib-based combination vs 7.3 months (95% CI, 5.6-9.3) with placebo in combination with palbociclib and fulvestrant (HR, 0.43; 95% CI, 0.32-0.59; P <.0001). Additionally, the objective response rate was 58% (95% CI, 50%-66%) vs 25% (95% CI, 19%-32%) in each respective arm, and the median duration of response was 18.4 months (95% CI, 10.4-22.2) vs 9.6 months (95% CI, 7.4-16.6), respectively. Although overall survival data did not reach statistical significance, investigators noted that these findings supported the overall risk/benefit profile of the inavolisib combination (HR, 0.64; 95% CI, 0.43-0.97).

Common toxicities in this trial included decreased neutrophil counts, decreased platelets, stomatitis, diarrhea, fatigue, and decreased potassium.

References

FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer. News release. FDA. October 10, 2024. Accessed October 10, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-inavolisib-palbociclib-and-fulvestrant-endocrine-resistant-pik3ca-mutated-hr-positive


Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content